Factor VIII-specific B cell responses in haemophilia A patients with inhibitors

Haemophilia

Volumn 16, Issue 102, 2010, Pages 35-43

  van Helden, P M W ^a   Van Haren, S D ^a   Fijnvandraat, K ^a   Marijke van den Berg, H ^b   Voorberg, J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Factor VIII; Haemophilia; Inhibitors; Memory B cells; Plasma cells

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; INTERLEUKIN 10; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; DISEASE SEVERITY; GENE FREQUENCY; GENETIC ASSOCIATION; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

B-LYMPHOCYTES; BLOOD COAGULATION FACTOR INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; RISK FACTORS;

EID: 77953208364     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02215.x     Document Type: Article

References (57)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001, 344:1773-9.
2. Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol 2006, 43:S18-22.
3. Lollar P. Pathogenic antibodies to coagulation factors. Part one: FVIII and factor IX. J Thromb Haemost 2004, 2:1082-95.
4. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived FVIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109:4693-7.
5. Fijnvandraat K, Celie PH, Turenhout EA. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998, 91:2347-52.
6. Fay PJ, Scandella D. Human inhibitor antibodies specific for the FVIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999, 274:29826-30.
7. Arai M, Scandella D, Hoyer LW. Molecular basis of FVIII inhibition by human antibodies. Antibodies that bind to the FVIII light chain prevent the interaction of FVIII with phospholipid. J Clin Invest 1989, 83:1978-84.
8. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with FVIII binding to factor IX. Blood 1998, 92:136-42.
9. Nogami K, Shima M, Nishiya K. Human FVIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed FVIII activation: a new anti-FVIII inhibitory mechanism. Thromb Haemost 2002, 87:459-65.
10. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-C2 domain antibodies are present in patients with FVIII inhibitors. Blood 2008, 112:1151-3.
11. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The humoral response to human FVIII in hemophilia A mice. J Thromb Haemost 2007, 5:512-9.
12. Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987, 69:1475-80.
13. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-FVIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002, 88:568-75.
14. van Helden PM, van den Berg HM, Gouw SC. IgG subclasses of anti-FVIII antibodies during ITI in patients with hemophilia A. Br J Haematol 2008, 142:644-52.
15. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996, 381:751-8.
16. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003, 29:23-30.
17. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006, 12(Suppl. 6):15-22.
18. Astermark J, Oldenburg J, Carlson J. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-45.
19. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-72.
20. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. JThromb Haemost 2007, 5:263-5.
21. Jones TD, Phillips WJ, Smith BJ. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of FVIII. J Thromb Haemost 2005, 3:991-1000.
22. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of FVIII. Thromb Haemost 1997, 77:238-42.
23. Hay CR, Ollier W, Pepper L. HLA class II profile: a weak determinant of FVIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997, 77:234-7.
24. Jacquemin M, Vantomme V, Buhot C. CD4+ T-cell clones specific for wild-type FVIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003, 101:1351-8.
25. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007, 5:1383-90.
26. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol 2007, 8:11-3.
27. von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia 2005, 11(Suppl. 1):18-23.
28. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977, 5:2306-8.
29. Mariani G, Siragusa S, Kroner BL. ITI in hemophilia A: a review. Semin Thromb Hemost 2003, 29:69-76.
30. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose ITI in hemophilia A patients with inhibitors. Blood 1995, 86:983-8.
31. Hausl C, Ahmad RU, Sasgary M. High-dose FVIII inhibits FVIII-specific memory B cells in hemophilia A with FVIII inhibitors. Blood 2005, 106:3415-22.
32. Tarlinton D. B-cell memory: are subsets necessary? Nat Rev Immunol 2006, 6:785-90.
33. van Helden PM, Kaijen PH, Fijnvandraat K, van den Berg HM, Voorberg J. FVIII-specific memory B cells in patients with hemophilia A. J Thromb Haemost 2007, 5:2306-8.
34. Lang I, Windyga J, Klukowska A, Ilas J, Schwartz HP, Reipert BM. Towards the detection of FVIII-specific memory B cells in hemophilia A patients with FVIII inhibitors. 35th Haemophilia Symposium 2006, In, Hamburg, Springer Verlag
35. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171:4969-73.
36. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004, 286:111-22.
37. Wen L, Hanvanich M, Werner-Favre C, Brouwers N, Perrin LH, Zubler RH. Limiting dilution assay for human B cells based on their activation by mutant EL4 thymoma cells: total and antimalaria responder B cell frequencies. Eur J Immunol 1987, 17:887-92.
38. Dohmen SE, Mulder A, Verhagen OJ, Eijsink C, Franke-van Dijk ME, van der Schoot CE. Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies. J Immunol Methods 2005, 298:9-20.
39. Mulder A, Eijsink C, Kardol MJ. Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol 2003, 171:6599-603.
40. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-89.
41. Fondere JM, Huguet MF, Macura-Biegun A. Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004, 35:114-9.
42. Tuaillon E, Tabaa YA, Petitjean G. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBVimmunized subjects by ELISPOT assay. J Immunol Methods 2006, 315:144-52.
43. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-202.
44. van den Brink EN, Timmermans SM, Turenhout EA. Longitudinal analysis of FVIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593->Cys substitution. Thromb Haemost 1999, 81:723-6.
45. Moreau A, Lacroix-Desmazes S, Stieltjes N. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000, 95:3435-41.
46. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006, 18:265-70.
47. Tarlinton D, Radbruch A, Hiepe F, Dorner T. Plasma cell differentiation and survival. Curr Opin Immunol 2008, 20:162-9.
48. Radbruch A, Muehlinghaus G, Luger EO. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-50.
49. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8:363-72.
50. Crotty S, Ahmed R. Immunological memory in humans. Semin Immunol 2004, 16:197-203.
51. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005, 23:367-86.
52. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101:4500-4.
53. Hausl C, Maier E, Schwarz HP. Long-term persistence of anti-FVIII antibody-secreting cells in hemophilic mice after treatment with human FVIII. Thromb Haemost 2002, 87:840-5.
54. Lei TC, Scott DW. Induction of tolerance to FVIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005, 105:4865-70.
55. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman FVIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of FVIII activation. Blood 2007, 110:4234-42.
56. Hausl C, Ahmad RU, Schwarz HP. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood 2004, 104:115-22.
57. Dorner T, Radbruch A. Selecting B cells and plasma cells to memory. J Exp Med 2005, 201:497-9.